GLP-1 drugs may be hailed as a medical breakthrough in obesity care, but Indian experts warn they are no cosmetic quick-fix.

Demand for weight-loss drugs is rising at a fast clip in India, where rivals Eli Lilly and Novo Nordisk are competing for ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

NEW DELHI – India is witnessing a sharp rise in the demand for obesity and diabetes medications, with urban populations ...

Sales of Eli Lilly’s Mounjaro double in a month; Novo Nordisk’s Wegovy enters market amid rising obesity and diabetes rates.

Incidence of obesity and diabetes is rising in India, the world's most populous country, which also ranks among the worst ...

Eli LillyDemand for weight-loss drugs in India has shot up.And rivals Novo Nordisk and Eli Lilly are battling for market ...

Mumbai: Mumbai-based pharma giant Cipla is gearing up to make an entry into India's rapidly growing weight management market, ...

New Delhi: Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang ...

Cipla Limited is planning to enter the weight management segment in India, announced the company’s MD and global CEO Umang ...

The health sector is witnessing notable developments, including the rising demand for obesity drugs in India as Eli Lilly and ...